New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
07:34 EDTPOZNPOZEN presents PA32540 Phase 3 data
POZEN presented data from the combined results of two Phase 3 studies of PA32540, an antiplatelet therapy of enteric-coated and immediate-release omeprazole, in patients with previous cerebrovascular disease. These data were presented at the American Heart Association 2013 International Stroke Conference. According to the studies, in the post-hoc analysis of subjects with a history of transient ischemic attack or stroke, long-term treatment with PA32540, compared to EC-ASA, was associated with a significantly reduced rate of endoscopic gastroduodenal ulcers, and study discontinuation due to adverse pre-specified upper GI events. The incidence of adjudicated major adverse cardiac events was similar for PA32540 and EC-ASA. Key Findings of the Study: PA32540 is associated with a lower rate of endoscopic gastroduodenal mucosal injury with a similar cerebrovascular event profile as EC-ASA therapy; PA32540, a single tablet containing EC aspirin and IR omeprazole, has a lower rate of discontinuation and, hence, may improve long-term adherence to ASA therapy.
News For POZN From The Last 14 Days
Check below for free stories on POZN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 16, 2014
07:31 EDTPOZNPOZEN announces FDA appectance of PA8140/PA32540 NDA refiling
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use